.Pharmacolibrary.Drugs.ATC.B.B01AC07 .Pharmacolibrary.Drugs.ATC.B.B01AC07| name: | Dipyridamole |
| ATC code: | B01AC07 | route: | oral |
| n-compartments | 2 |
Dipyridamole is an antiplatelet agent that inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, thereby increasing local concentrations of adenosine, which leads to platelet inhibition and vasodilation. It is commonly used for prevention of thromboembolic events and as an adjunct to oral anticoagulation in patients with prosthetic heart valves. It is also used in conjunction with aspirin for secondary prevention of stroke. Dipyridamole is an approved drug and remains in clinical use.
Pharmacokinetics after oral administration of 75 mg dipyridamole tablets in healthy adult volunteers (both sexes), fasting conditions.
Curtin, R, & Fitzgerald, DJ (2002). Pharmacogenetics of antiplatelet drugs. TheScientificWorldJournal 2 791–800. DOI:10.1100/tsw.2002.153 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12806004
Silva, MI, et al., & Halbert, GW (2023). Fed intestinal solubility limits and distributions applied to the Developability classification system. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 186 74–84. DOI:10.1016/j.ejpb.2023.03.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36934829
Yamamoto, H, et al., & Sugano, K (2023). Application of Population Balance Model to Simulate Precipitation of Weak Base and Zwitterionic Drugs in Gastrointestinal pH Environment. Molecular pharmaceutics 20(4) 2266–2275. DOI:10.1021/acs.molpharmaceut.3c00088 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36929729